Methacholine delays pulmonary absorption of inhaled β2-agonists due to competition for organic cation/carnitine transporters

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 1, 2012, Pages 124-134

  Gnadt, Mirjam ^a   Trammer, Beatrice ^a   Freiwald, Matthias ^a,e   Kardziev, Boris ^b   Bayliss, Martin K ^c   Edwards, Chris D ^c   Schmidt, Michael ^a   Friedel, Godehard ^d   Högger, Petra ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Thoraxzentrum Bezirk Unterfranken   (Germany)

^c GLAXOSMITHKLINE   (United Kingdom)

^d Klinik Schillerhohe   (Germany)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Carnitine; GW597901; Methacholine; OCTN2; Pulmonary absorption; Salbutamol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARNITINE; GSK 597901; METHACHOLINE; ORGANIC CATION TRANSPORTER; SALBUTAMOL;

ADULT; AGED; ARTICLE; BRONCHOSPASM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG RELEASE; DRUG TISSUE LEVEL; FEMALE; HUMAN; LIPOPHILICITY; LUNG FUNCTION; LUNG PERFUSION; MALE; NEBULIZATION; PRIORITY JOURNAL; REPERFUSION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AEROSOLS; AGED; ALBUTEROL; ALGORITHMS; AREA UNDER CURVE; BINDING, COMPETITIVE; BRONCHOCONSTRICTION; BRONCHOCONSTRICTOR AGENTS; CARNITINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDICATORS AND REAGENTS; LUNG; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED; ORGANIC CATION TRANSPORT PROTEINS; PERFUSION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84856767879     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.12.009     Document Type: Article

References (28)

1. Bateman E.D., Hurd S.S., Barnes P.J., Bousquet J., Drazen J.M., FitzGerald M., et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008, 31:143-178.
2. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
3. Cazzola M., Matera M.G., Lötvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005, 14:775-783.
4. Procopiou P.A., Barrett V.J., Bevan N.J., Biggadike K., Butchers P.R., Coe D.M., et al. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups. JMed Chem 2009, 52:2280-2288.
5. Borgström L., Nilsson M. Amethod for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline. Pharm Res 1990, 7:1068-1070.
6. Daley-Yates P.T., Price A.C., Sisson J.R., Pereira A., Dallow N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001, 51:400-409.
7. Lahelma S., Kirjavainen M., Kela M., Herttuainen J., Vahteristo M., Silvasti M., et al. Equivalent lung deposition of budesonide invivo: a comparison of dry powder inhalers using a pharmacokinetic method. Br J Clin Pharmacol 2005, 59:167-173.
8. Grainge C.L., Lau L.C., Ward J.A., Dulay V., Lahiff G., Wilson S., et al. Effect of bronchoconstriction on airway remodeling in asthma. NEngl J Med 2011, 364:2006-2015.
9. Dalby C., Polanowski T., Larsson T., Borgström L., Edsbäcker S., Harrison T.W. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir Res 2009, 10:104.
10. Mortimer K.J., Tattersfield A.E., Tang Y., Wu K., Lewis S., Hochhaus G., et al. Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction. Br J Clin Pharmacol 2007, 64:439-444.
11. Saari S.M., Vidgren M.T., Koskinen M.O., Turjanmaa V.M., Waldrep J.C., Nieminen M.M. Regional lung deposition and clearance of 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma. Chest 1998, 113:1573-1579.
12. Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 2005, 172:1497-1504.
13. Freiwald M., Valotis A., Kirschbaum A., McClellan M., Mürdter T., Fritz P., et al. Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model. Respir Res 2005, 6:21.
14. Woodcock A., Acerbi D., Poli G. Modulite technology: pharmacodynamic and pharmacokinetic implications. Respir Med 2002, 96(Suppl D):S9-15.
15. Laube B.L., Jashnani R., Dalby R.N., Zeitlin P.L. Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. Chest 2000, 118:1069-1076.
16. van Waarde A., Maas B., Doze P., Slart R.H., Frijlink H.W., Vaalburg W., et al. Positron emission tomography studies of human airways using an inhaled beta-adrenoceptor antagonist, S-11C-CGP 12388. Chest 2005, 128:3020-3027.
17. Silkstone V.L., Corlett S.A., Chrystyn H. Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization. Br J Clin Pharmacol 2002, 54:115-119.
18. Koepsell H., Lips K., Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007, 24:1227-1251.
19. Bosquillon C. Drug transporters in the lung-do they play a role in the biopharmaceutics of inhaled drugs?. JPharm Sci 2010, 99:2240-2255.
20. Horvath G., Schmid N., Fragoso M.A., Schmid A., Conner G.E., Salathe M., et al. Epithelial organic cation transporters ensure pH-dependent drug absorption in the airway. Am J Respir Cell Mol Biol 2007, 36:53-60.
21. van der Deen M., de Vries E.G., Timens W., Scheper R.J., Timmer-Bosscha H., Postma D.S. ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res 2005, 6:59.
22. Ehrhardt C., Kneuer C., Bies C., Lehr C.M., Kim K.J., Bakowsky U. Salbutamol is actively absorbed across human bronchial epithelial cell layers. Pulm Pharmacol Ther 2005, 18:165-170.
23. Nakamura T., Nakanishi T., Haruta T., Shirasaka Y., Keogh J.P., Tamai I. Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm 2010, 7:187-195.
24. Ohashi R., Tamai I., Nezu Ji J., Nikaido H., Hashimoto N., Oku A., et al. Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol 2001, 59:358-366.
25. Kummer W., Wiegand S., Akinci S., Wessler I., Schinkel A.H., Wess J., et al. Role of acetylcholine and polyspecific cation transporters in serotonin-induced bronchoconstriction in the mouse. Respir Res 2006, 7:65.
26. Kirby S., Falcoz C., Daniel M.J., Milleri S., Squassante L., Ziviani L., et al. Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Eur J Clin Pharmacol 2001, 56:781-791.
27. Tronde A., Gillen M., Borgstrom L., Lötvall J., Ankerst J. Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD. JClin Pharmacol 2008, 48:1300-1308.
28. Horvath G., Mendes E.S., Schmid N., Schmid A., Conner G.E., Salathe M., et al. The effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells. JAllergy Clin Immunol 2007, 120:1103-1109.